Athira Pharma, Inc. (LONA) Stock Analysis & Investment Frameworks
Athira Pharma, Inc. (LONA) stock analysis on Invetso. Review Athira Pharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Athira Pharma, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Athira Pharma, Inc. Key Financial Metrics
- Market Cap: $20.75M
- Revenue: $N/A
- ROE: -411.58%
- ROIC: -248.21%
- Dividend Yield: N/A
About Athira Pharma, Inc.
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Athira Pharma, Inc. Investment Frameworks
Invetso analyzes Athira Pharma, Inc. (LONA) across the following frameworks:
- Athira Pharma, Inc. 10Y Growth Potential
- Athira Pharma, Inc. Scenario Analysis
- Athira Pharma, Inc. Risks & Opportunities
- Athira Pharma, Inc. Economic Moat
- Athira Pharma, Inc. Business Model
- Athira Pharma, Inc. Management
- Athira Pharma, Inc. SWOT Analysis
- Athira Pharma, Inc. Porter's 5 Forces
- Athira Pharma, Inc. PESTLE Analysis
- Athira Pharma, Inc. ESG Analysis